Market cap
$16.8m
End-of-day close multiplied by current shares on issue.
TRU · NZX
Truscreen Group (TRU)
Healthcare / Medical diagnosticsCovered: HY22 - FY264 published briefings
Truscreen Group is an NZX-listed healthcare / medical diagnostics company. Its latest covered result is FY26, with HY22 - FY26 of source-backed result history on Annolyse.
Sections
Latest result
Latest metrics
FY26, released 29 May 2026
← Swipe to view more
| Metric | Value | Change |
|---|---|---|
| Revenue | $2.4m | ↑ +45.0% |
| EBITDA | -$2.2m | — |
| NPAT | -$2.3m | ↑ +70.9% |
| Operating cash flow | -$2.5m | ↑ +2.4% |
| OCF / EBITDA % | 112.3% | — |
| ROE % | -87.1% | — |
| PBT | -$2.3m | ↑ +70.9% |
| FCF pre-lease | -$2.5m | ↑ +2.5% |
| Debtor days | 154 | ↑ +157.0% |
| Inventory days | 99 | ↓ -8.4% |
Source: latest published briefing (FY26, released 29 May 2026). Change compares against the prior equivalent period: FY22, released 30 May 2022.
Valuation
Valuation
Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.
Prices as at close, 3 September 2026
Price and market cap
The latest close and share count context for the market price.
i
Profitability multiples
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.00
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not meaningful when recent EBITDA is negative.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
6.48x
Market value compared with latest reported equity.
Income and investment-company measures
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Price history
Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.
Share price
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Loading chart...
Chat
Ask about TRU
Ask follow-up questions about Truscreen Group's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Ask about TRU
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Financial history
Performance over time
The latest period is shown first.
← Swipe to view more
| Metric | FY2612 MONTHS29 May 2026 | HY236 MONTHS29 November 2022 | FY2212 MONTHS30 May 2022 | HY226 MONTHS29 November 2021 | Trend |
|---|---|---|---|---|---|
| Revenue | $2.4m | $0.74m | $1.7m | $0.75m | Chart |
| Revenue growth % | 42.2% | -0.7% | 48.2% | 24.8% | Chart |
| EBITDA | -$2.2m | -$1.2m | — | -$1.3m | Chart |
| EBITDA margin % | -90.4% | -164.9% | — | -169.0% | Chart |
| PBT | -$2.3m | -$1.2m | -$7.9m | -$1.3m | Chart |
| NPAT | -$2.3m | -$1.2m | -$7.9m | -$1.3m | Chart |
| Operating cash flow | -$2.5m | -$1.2m | -$2.5m | -$1.7m | Chart |
| OCF / EBITDA % | 112.3% | 99.7% | — | 136.6% | Chart |
| FCF pre-lease | -$2.5m | -$1.2m | -$2.5m | -$1.7m | Chart |
| FCF post-lease | — | -$1.2m | — | -$1.7m | Chart |
| DPS | — | 0.0c | — | 0.0c | Chart |
| ROE % | -87.1% | -51.9% | n/m | -13.0% | Chart |
| Net debt | — | — | — | -$3.7m | — |
| Net debt / EBITDA | — | — | — | 2.92x | — |
| Debtor days | 154 | 37 | 60 | 2 | Chart |
| Inventory days | 99 | 174 | 108 | 169 | Chart |
| Total assets | $3.7m | $2.9m | $4.4m | $10.3m | Chart |
Reference: annolyse.ai/companies/tru
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
Filing-only history charts
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Revenue
Reported revenue across covered periods.
Loading chart...
Revenue growth
Like-period revenue growth where comparable.
Loading chart...
EBITDA-equivalent
Company-specific earnings measure where disclosed.
Loading chart...
EBITDA margin
EBITDA-equivalent margin where revenue and earnings are source-backed.
Loading chart...
NPAT
Statutory profit after tax.
Loading chart...
Operating cash flow
Cash generated from operations.
Loading chart...
More financial metrics
Additional filing-backed metrics for this company. Each point links to the relevant published briefing.
FCF pre-lease
Operating cash flow less capex before leases.
Loading chart...
FCF post-lease
Free cash flow after lease payments where available.
Loading chart...
ROE
Return on equity.
Loading chart...
Net debt
Borrowings less cash; negative values indicate net cash.
Loading chart...
DPS
Dividend per share declared for the period.
Loading chart...
Debtor days
Receivables days where the working-capital inputs are source-backed.
Loading chart...
Inventory days
Inventory days where the working-capital inputs are source-backed.
Loading chart...
The setup & the reality
HY23 → FY26 Follow-through
The latest result is checked against what the prior briefing said to watch.
Historical setup
What HY23 said to watch
Previous analysisHY23Result releasedAnnolyse analysis published
From Cash down to $1.7m as $1.2m HY operating burn continues
No forward revenue or earnings target is provided in the release. The FY22 shape is not a clean seasonality guide: HY22 carried 44.4% of FY22 revenue but only 16% of FY22 NPAT, and that asymmetry sits in the FY22 impairment booked in the second half rather than a recurring 2H business pattern. On revenue alone, an annualised run-rate of approximately $1.5m sits below FY22 product revenue of $1.7m, so matching last year would require a stronger second half.
Management commentary cites China lockdown disruption and continued expansion in private health-check channels but provides no quantified outlook against which this half can be judged.
Open questions
Open questions from HY23
- What is the expected cash runway at the current burn rate, and is a capital raise contemplated within the next 12 months?
- How much of the soft China revenue is COVID-related versus structural channel-access issues?
- Why have trade receivables risen from $7k to $150k, and what is the customer concentration and collection profile?
- What SUS consumable volume and pricing trajectory does management expect in 2H, and from which geographies?
- Will the cost base be reduced if revenue acceleration does not materialise in the second half?
This briefing cannot assess management's specific cash runway forecast or capital plan because no quantified outlook or funding guidance was disclosed.
Latest result sources
Primary issuer documents used for the FY26 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.
Current period
TruScreen FY2026 Prelimnary Final Results
FY26 / financial reportTruScreen FY2026 Prelimnary Final Results Presentation
FY26 / results presentationTruScreen Prelimnary Final FY2026 Results Commentary
FY26 / results releaseTruScreen Results FY2026 Summary
FY26 / results announcementPrior comparable period
Truscreen Annual Report 31 March 2025
FY25 / financial reportInterim context
Truscreen Commentary on Half Year Results
HY26 / results releaseTruscreen Interim Financial Report September 2026
HY26 / financial reportTruscreen Results Summary September 2025
HY26 / results announcementPeer context
Other covered Healthcare companies
These companies share a broad sector but may not be direct peers. Compare them only where the underlying measures are genuinely comparable.
Archive
Briefing archive
The full chronological archive contains every published result briefing.
FY26 · Released 29 May 2026
Revenue up 42% but missed $2.8m guidance as debtors swelled to $1.0m
A 140bps gross margin lift is real, but a $1.0m receivables build and ongoing $2.5m operating cash burn keep the runway question open.
Read briefing
HY23 · Released 29 November 2022
Cash down to $1.7m as $1.2m HY operating burn continues
Operating cash outflow narrowed 29.3% to $1.2m, but at $0.74m half-year revenue, runway is now the central question.
Read briefing
FY22 · Released 30 May 2022
Revenue grew 48% but FY22 loss widened to $7.9m as cash fell to $2.8m
Operating leverage moved the wrong way in the second half, with the implied H2 loss running roughly five times H1 and cash burn consuming nearly half
Read briefing
HY22 · Released 29 November 2021
Operating cash burn widened to NZ$1.7m as cash fell to NZ$3.7m
Reported loss narrowed in dollar terms but operating cash outflow grew, drawing cash down 17.8% and total equity 13.4% over the period.
Read briefing
Get notified when TRU publishes
Get the next Truscreen Group result briefing and five-year history updates by email.